Russian clinical practice guidelines «congenital adrenal hyperplasia»

Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive diseases characterized by a defect in one of the enzymes or transport proteins involved in the cortisol synthesis in the adrenal cortex. The most common form of CAH, which occurs in more than 90% of cases, is a 21-hydroxylase enzyme deficiency. The latter is subdivided into nonclassical and classic (salt-losing and virilizing) forms. The prevalence of classic forms of 21-hydroxylase deficiency ranges from 1: 14,000 to 1:18,000 live births worldwide. According to the data of neonatal screening in the Russian Federation, the prevalence of the disease in some regions ranges from 1: 5000 to 1: 12000, in the country as a whole - 1: 9638 live newborns. The non-classical form of CAH occurs more often - from 1: 500 to 1: 1000 among the general population. In second place is the hypertensive form of CAH - a deficiency of 11β-hydroxylase, which, according to the literature, occurs in about 1 per 100,000 newborns. These clinical guidelines were compiled by a professional community of narrow specialists, approved by the expert council of the Ministry of Health of the Russian Federation, and updated the previous version published in 2016. The clinical guidelines are based on systematic reviews, meta-analyses and original articles, and scientific work on this issue in the Russian Federation and other countries. The purpose of this document is to provide clinicians with the most up-to-date, evidence-based guidelines for the CAH diagnosis and treatment

1. Melnichenko GA, Troshina EA, Molashenko NV,et al. Russian Association of Endocrinologists clinical practice guidelinesfor diagnosis, treatment and preventive measures in congenital adrenalhyperplasia due to 21-hydroxylase deficiency patients in adulthood.Consilium Medicum. 2016;18(4):8-19. (In Russ.).

2. Kareva MA, Chugunov IS. Federal clinical practice guidelines onthe management of the patients presenting with congenital adrenalhyperplasia. Problems of Endocrinology. 2014;60(2):42-50. (In Russ.) doi: https://doi.org/10.14341/probl201460242-50

3. Speiser PW, Arlt W, Auchus RJ, et al. Congenital Adrenal Hyperplasia Dueto Steroid 21-Hydroxylase Deficiency: An Endocrine Society ClinicalPractice Guideline. J Clin Endocrinol Metab. 2018;103(11):4043-4088.doi: https://doi.org/10.1210/jc.2018-01865

4. Sazonova AI. Somaticheskii statusi metabolicheskie narusheniya u vzroslykh patsientov s razlichnymiformami VDKN [dissertation]. Moscow; 2013. (In Russ.).

5. Kareva MA. Vrozhdennaya disfunktsiya kory nadpochechnikov u detei:epidemiologiya, geneticheskaya osnova, personalizirovannyi podkhodk diagnostike i lecheniyu, monitoring somaticheskogo i reproduktivnogozdorov’ya [dissertation]. Moscow; 2019. (In Russ.).

6. Endokrinologiya.Natsional’noe rukovodstvo. Ed by Dedov II, Mel’nichenko GA. Moscow:GEOTAR-Media; 2016. (In Russ.).

7. KunayevaOV, Zernova LYu, Kovalenko TV, Osipova YeV. The summing up andperspectives of neonatal screening of inherent dysfunction of suprarenal cortex: the regional aspects. Lechenie i profilaktika. 2014;9(1):10-15(In Russ.).

8. Svinarev MYu, Andreeva LP, Arakovich VV, et al. Neonatal’nyi skriningna VDKN v Saratovskoi oblasti // Sbornik tezisov Vseros. konf. pediatrovendokrinologov «Dostizheniya endokrinologii — zdorov’yu detei».Moscow; 2011:19-20(In Russ.).

9. Khramova EB.Epidemiologiya, skrining, diagnostika vrozhdennoi disfunktsii korynadpochechnikov v Zapadno-Sibirskom regione [dissertation]. Tyumen’;2013. (In Russ.).

10. Gidlöf S, Wedell A, Guthenberg C, et al. NationwideNeonatal Screening for Congenital Adrenal Hyperplasiain Sweden. JAMA Pediatr. 2014;168(6):567-574.doi: https://doi.org/10.1001/jamapediatrics.2013.5321

11. van der Kamp H, Wit J. Neonatal screening for congenitaladrenal hyperplasia. Eur J Endocrinol. 2004;151(3):U71-U75.doi: https://doi.org/10.1530/eje.0.151u071

12. Pang S, Shook MK. Current status of neonatal screening forcongenital adrenal hyperplasia. Curr Opin Pediatr. 1997;9(4):419-423.doi: https://doi.org/10.1097/00008480-199708000-00018

13. Therrell BL. Newborn screening for congenital adrenalhyperplasia. Endocrinol Metab Clin North Am. 2001;30(1):15-30.doi: https://doi.org/10.1016/S0889-8529(08)70017-3

14. Brosnan PG, Brosnan CA, Kemp SF, et al. Effect of Newborn Screeningfor Congenital Adrenal Hyperplasia. Arch Pediatr Adolesc Med.1999;153(12):1272-1278. doi: https://doi.org/10.1001/archpedi.153.12.1272

15. Gidlöf S, Falhammar H, Thilén A, et al. One hundred years of congenitaladrenal hyperplasia in Sweden: a retrospective, populationbased cohort study. Lancet Diabetes Endocrinol. 2013;1(1):35-42.doi: https://doi.org/10.1016/S2213-8587(13)70007-X

16. Armengaud J-B, Charkaluk M-L, Trivin C, et al. Precocious Pubarche:Distinguishing Late-Onset Congenital Adrenal Hyperplasia fromPremature Adrenarche. J Clin Endocrinol Metab. 2009;94(8):2835-2840.doi: https://doi.org/10.1210/jc.2009-0314

17. Bidet M, Bellanné-Chantelot C, Galand-Portier M-B, et al. Clinical andMolecular Characterization of a Cohort of 161 Unrelated Women withNonclassical Congenital Adrenal Hyperplasia Due to 21-HydroxylaseDeficiency and 330 Family Members. J Clin Endocrinol Metab.2009;94(5):1570-1578. doi: https://doi.org/10.1210/jc.2008-1582

18. Török D, Halász Z, Garami M, et al. Limited Value of Serum SteroidMeasurements in Identification of Mild Form of 21-HydroxylaseDeficiency. Exp Clin Endocrinol Diabetes. 2003;111(01):27-32.doi: https://doi.org/10.1055/s-2003-37497

19. Azziz R, Hincapie LA, Knochenhauer ES, et al. Screening for21-hydroxylase–deficient nonclassic adrenal hyperplasia amonghyperandrogenic women: a prospective study. Fertil Steril.1999;72(5):915-925. doi: https://doi.org/10.1016/S0015-0282(99)00383-0

20. Speiser PW, White PC. Congenital adrenal hyperplasia due to steroid21-hydroxylase deficiency. Clin Endocrinol (Oxf). 1998;49(4):411-417.doi: https://doi.org/10.1046/j.1365-2265.1998.00559.x

21. Wedell A, Thilén A, Ritzén EM, et al. Mutational spectrum of the steroid21-hydroxylase gene in Sweden: implications for genetic diagnosisand association with disease manifestation. J Clin Endocrinol Metab.1994;78(5):1145-1152. doi: https://doi.org/10.1210/jcem.78.5.8175971

22. Lacey JM, Minutti CZ, Magera MJ, et al. Improved Specificity of NewbornScreening for Congenital Adrenal Hyperplasia by Second-TierSteroid Profiling Using Tandem Mass Spectrometry. Clin Chem.2004;50(3):621-625. doi: https://doi.org/10.1373/clinchem.2003.027193

23. Rauh M, Gröschl M, Rascher W, Dörr HG. Automated, fastand sensitive quantification of 17α-hydroxy-progesterone,androstenedione and testosterone by tandem massspectrometry with on-line extraction. Steroids. 2006;71(6):450-458.doi: https://doi.org/10.1016/j.steroids.2006.01.015

24. Janzen N, Peter M, Sander S, et al. Newborn Screening for CongenitalAdrenal Hyperplasia: Additional Steroid Profile using LiquidChromatography-Tandem Mass Spectrometry. J Clin Endocrinol Metab.2007;92(7):2581-2589. doi: https://doi.org/10.1210/jc.2006-2890

25. Minutti CZ, Lacey JM, Magera MJ, et al. Steroid Profiling by TandemMass Spectrometry Improves the Positive Predictive Value of NewbornScreening for Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab.2004;89(8):3687-3693. doi: https://doi.org/10.1210/jc.2003-032235

26. Matern D, Tortorelli S, Oglesbee D, et al. Reduction of the false-positiverate in newborn screening by implementation of MS/MS-based secondtier tests: The Mayo Clinic experience (2004–2007). J Inherit Metab Dis. 2007;30(4):585-592. doi: https://doi.org/10.1007/s10545-007-0691-y

27. Schwarz E, Liu A, Randall H, et al. Use of Steroid Profiling by UPLC-MS/MSas a Second Tier Test in Newborn Screening for Congenital AdrenalHyperplasia: The Utah Experience. Pediatr Res. 2009;66(2):230-235.doi: https://doi.org/10.1203/PDR.0b013e3181aa3777

28. Seo JY, Park H-D, Kim JW, et al. Steroid profiling for congenital adrenalhyperplasia by tandem mass spectrometry as a second-tier testreduces follow-up burdens in a tertiary care hospital: A retrospectiveand prospective evaluation. J Perinat Med. 2014;42(1);121-127.doi: https://doi.org/10.1515/jpm-2013-0154

29. New MI. Nonclassical 21-Hydroxylase Deficiency. J Clin Endocrinol Metab.2006;91(11):4205-4214. doi: https://doi.org/10.1210/jc.2006-1645

30. Merke DP, Bornstein SR. Congenital adrenalhyperplasia. Lancet. 2005;365(9477):2125-2136.doi: https://doi.org/10.1016/S0140-6736(05)66736-0

31. Abdu TAM, Elhadd TA, Neary R, Clayton RN. Comparison of the LowDose Short Synacthen Test (1 μg), the Conventional Dose ShortSynacthen Test (250 μg), and the Insulin Tolerance Test forAssessment of the Hypothalamo-Pituitary-Adrenal Axis in Patientswith Pituitary Disease. J Clin Endocrinol Metab. 1999;84(3):838-843.doi: https://doi.org/10.1210/jcem.84.3.5535

32. Silveira E, Elnecave R, dos Santos E, et al. Molecular analysis of CYP21A2can optimize the follow-up of positive results in newborn screeningfor congenital adrenal hyperplasia. Clin Genet. 2009;76(6):503-510.doi: https://doi.org/10.1111/j.1399-0004.2009.01274.x

33. Blanché H, Vexiau P, Clauin S, et al. Exhaustivescreening of the 21-hydroxylase gene in a populationof hyperandrogenic women. Hum Genet. 1997;101(1):56-60.doi: https://doi.org/10.1007/s004390050586

34. Deneux C, Tardy V, Dib A, et al. Phenotype-Genotype Correlationin 56 Women with Nonclassical Congenital Adrenal Hyperplasia due to21-Hydroxylase Deficiency. J Clin Endocrinol Metab. 2001;86(1):207-213.doi: https://doi.org/10.1210/jcem.86.1.7131

35. Yang Y. Reverse dot-blot hybridization as an improved tool forthe molecular diagnosis of point mutations in congenital adrenalhyperplasia caused by 21-hydroxylase deficiency. Mol Diagnosis.2001;6(3):193-199. doi: https://doi.org/10.1054/modi.2001.26587

36. Fitness J. Genotyping of CYP21, Linked Chromosome 6p Markers,and a Sex-Specific Gene in Neonatal Screening for CongenitalAdrenal Hyperplasia. J Clin Endocrinol Metab. 1999;84(3):960-966.doi: https://doi.org/10.1210/jc.84.3.960

37. Németh S, Riedl S, Kriegshäuser G, et al. Reverse-hybridization assay forrapid detection of common CYP21A2 mutations in dried blood spotsfrom newborns with elevated 17-OH progesterone. Clin Chim Acta.2012;414:211-214. doi: https://doi.org/10.1016/j.cca.2012.09.013

38. Costa-Barbosa FA, Carvalho VM, Nakamura OH, et al. Zona fasciculata21-hydroxysteroids and precursor-to-product ratios in 21-hydroxylasedeficiency: Further characterization of classic and non-classic patientsand heterozygote carriers. J Endocrinol Invest. 2011;34(8):587-592.doi: https://doi.org/10.3275/7273

39. Balsamo A, Cacciari E, Baldazzi L, et al. CYP21 analysis and phenotype/genotype relationship in the screened population of the ItalianEmilia-Romagna region. Clin Endocrinol (Oxf). 2000;53(1):117-125.doi: https://doi.org/10.1046/j.1365-2265.2000.01048.x

40. Wedell A, Ritzen EM, Haglund-Stengler B, Luthman H. Steroid21-hydroxylase deficiency: three additional mutated allelesand establishment of phenotype-genotype relationshipsof common mutations. Proc Natl Acad Sci. 1992;89(15):7232-7236.doi: https://doi.org/10.1073/pnas.89.15.7232

41. Claahsen-van der Grinten HL, Dehzad F, Kamphuis-van Ulzen K, de KorteCL. Increased prevalence of testicular adrenal rest tumours duringadolescence in congenital adrenal hyperplasia. Horm Res Paediatr.2014;82(4):238-244. doi: https://doi.org/10.1159/000365570

42. Claahsen-van der Grinten HL, Otten BJ, Takahashi S, et al. Testicularadrenal rest tumors in adult males with congenital adrenal hyperplasia:evaluation of pituitary-gonadal function before and after successfultestis-sparing surgery in eight patients. J Clin Endocrinol Metab.2007;92(2):612-615. doi: https://doi.org/10.1210/jc.2006-1311

43. Auchus RJ, Arlt W. Approach to the Patient: The Adult With CongenitalAdrenal Hyperplasia. J Clin Endocrinol Metab. 2013;98(7):2645-2655.doi: https://doi.org/10.1210/jc.2013-1440

44. Reisch N, Rottenkolber M, Greifenstein A, et al. Testicular AdrenalRest Tumors Develop Independently of Long-Term Disease Control:A Longitudinal Analysis of 50 Adult Men With Congenital AdrenalHyperplasia due to Classic 21-Hydroxylase Deficiency. J Clin EndocrinolMetab. 2013;98(11):E1820-E1826. doi: https://doi.org/10.1210/jc.2012-3181

45. Falhammar H, Nyström HF, Ekström U, et al. Fertility, sexuality and testicularadrenal rest tumors in adult males with congenital adrenal hyperplasia. EurJ Endocrinol. 2012;166(3):441-449. doi: https://doi.org/10.1530/EJE-11-0828

46. Reisch N, Flade L, Scherr M, et al. High Prevalence of Reduced Fecundityin Men with Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab.2009;94(5):1665-1670. doi: https://doi.org/10.1210/jc.2008-1414

47. Stikkelbroeck NMML, Otten BJ, Pasic A, et al. High Prevalenceof Testicular Adrenal Rest Tumors, Impaired Spermatogenesis,and Leydig Cell Failure in Adolescent and Adult Males with CongenitalAdrenal Hyperplasia. J Clin Endocrinol Metab. 2001;86(12):5721-5728.doi: https://doi.org/10.1210/jcem.86.12.8090

48. Martinez-Aguayo A, Rocha A, Rojas N, et al. Testicular AdrenalRest Tumors and Leydig and Sertoli Cell Function in Boys withClassical Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab.2007;92(12):4583-4589. doi: https://doi.org/10.1210/jc.2007-0383

49. Stikkelbroeck NMML, Hermus ARMM, Suliman HM, et al. AsymptomaticTesticular Adrenal Rest Tumours in Adolescent and Adult Males withCongenital Adrenal Hyperplasia: Basal and Follow-up InvestigationAfter 2.6 Years. J Pediatr Endocrinol Metab. 2004;17(4):645-653.doi: https://doi.org/10.1515/JPEM.2004.17.4.645

50. Bouvattier C, Esterle L, Renoult-Pierre P, et al. Clinical Outcome,Hormonal Status, Gonadotrope Axis, and Testicular Function in 219Adult Men Born With Classic 21-Hydroxylase Deficiency. A FrenchNational Survey. J Clin Endocrinol Metab. 2015;100(6):2303-2313.doi: https://doi.org/10.1210/jc.2014-4124

51. Cabrera MS. Long Term Outcome in Adult Males with Classic CongenitalAdrenal Hyperplasia. J Clin Endocrinol Metab. 2001;86(7):3070-3078.doi: https://doi.org/10.1210/jc.86.7.3070

52. Jääskeläinen J, Voutilainen R. Long-term outcomeof classical 21-hydroxylase deficiency: diagnosis, complicationsand quality of life. Acta Paediatr. 2000;89(2):183-187.doi: https://doi.org/10.1080/080352500750028807

53. Chen H, Huang L, Zhong Z, et al. Ovarian Adrenal Rest TumorsUndetected by Imaging Studies and Identified at Surgery in ThreeFemales with Congenital Adrenal Hyperplasia Unresponsive toIncreased Hormone Therapy Dosage. Endocr Pathol. 2017;28(2):146-151.doi: https://doi.org/10.1007/s12022-016-9461-4

54. Zaarour M, Atallah D, Trak-Smayra V, Halaby G. Bilateral Ovary Adrenal RestTumor in a Congenital Adrenal Hyperplasia Following Adrenalectomy.Endocr Pract. 2014;20(4):e69-e74. doi: https://doi.org/10.4158/EP13092.CR

55. Tiosano D, Vlodavsky E, Filmar S, et al. Ovarian Adrenal Rest Tumorin a Congenital Adrenal Hyperplasia Patient with AdrenocorticotropinHypersecretion following Adrenalectomy. Horm Res Paediatr.2010;74(3):223-228. doi: https://doi.org/10.1159/000295722

56. Pina C, Khattab A, Katzman P, et al. Ovarian carcinoma in a 14-year-oldwith classical salt-wasting congenital adrenal hyperplasia and bilateraladrenalectomy. J Pediatr Endocrinol Metab. 2015;28(5-6):663-667.doi: https://doi.org/10.1515/jpem-2014-0299

57. Mellis AM, Palmer BW, Wisniewski AB, Slobodov G. Ovarianadrenal rest tumour in a patient with chronically untreatedcongenital adrenal hyperplasia (CAH). BJUI. July 2011.doi: https://doi.org/10.1002/BJUIw-2011-041-web

58. Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prevalence and naturalhistory of adrenal incidentalomas. Eur J Endocrinol. 2003;149(4):273-285.doi: https://doi.org/10.1530/eje.0.1490273

59. Kloos RT, Gross MD, Francis IR, et al. Incidentally DiscoveredAdrenal Masses*. Endocr Rev. 1995;16(4):460-484.doi: https://doi.org/10.1210/edrv-16-4-460

60. Jaresch S, Kornely E, Kley HK, Schlaghecke R. Adrenal incidentalomaand patients with homozygous or heterozygous congenitaladrenal hyperplasia. J Clin Endocrinol Metab. 1992;74(3):685-689.doi: https://doi.org/10.1210/jcem.74.3.1311000

61. Barzon L, Maffei P, Sonino N, et al. The role of 21-hydroxylasein the pathogenesis of adrenal masses: Review of the literatureand focus on our own experience. J Endocrinol Invest. 2007;30(7):615-623.doi: https://doi.org/10.1007/BF03346358

62. Varan A, Unal S, Ruacan S, Vidinlisan S. Adrenocortical carcinomaassociated with adrenogenital syndrome in a child. Med PediatrOncol. 2000;35(1):88-90. doi: https://doi.org/10.1002/1096-1X(200007)35:1<88::AID-MPO18>3.0.CO;2-I

63. Nermoen I, Rørvik J, Holmedal SH, et al. High frequency of adrenalmyelolipomas and testicular adrenal rest tumours in adult Norwegianpatients with classical congenital adrenal hyperplasia becauseof 21-hydroxylase deficiency. Clin Endocrinol (Oxf). 2011;75(6):753-759.doi: https://doi.org/10.1111/j.1365-2265.2011.04151.x

64. Muthusamy K, Elamin MB, Smushkin G, et al. Adult Height in Patientswith Congenital Adrenal Hyperplasia: A Systematic Reviewand Metaanalysis. J Clin Endocrinol Metab. 2010;95(9):4161-4172.doi: https://doi.org/10.1210/jc.2009-2616

65. Frisch H, Battelino Τ, Schober Ε, et al. Salt Wasting in Simple VirilizingCongenital Adrenal Hyperplasia. J Pediatr Endocrinol Metab.2001;14(9):1649-1655. doi: https://doi.org/10.1515/JPEM.2001.14.9.1649

66. Punthakee Z, Legault L, Polychronakos C.Prednisolone in the treatment of adrenal insufficiency:a re-evaluation of relative potency. J Pediatr. 2003;143(3):402-405.doi: https://doi.org/10.1067/S0022-3476(03)00294-4

67. Rivkees SA, Crawford JD. Dexamethasone Treatmentof Virilizing Congenital Adrenal Hyperplasia:The Ability to Achieve Normal Growth. Pediatrics. 2000;106(4):767-773.doi: https://doi.org/10.1542/peds.106.4.767

68. Sarafoglou K, Gonzalez-Bolanos MT, Zimmerman CL, et al. Comparisonof cortisol exposures and pharmacodynamic adrenal steroid responsesto hydrocortisone suspension vs. commercial tablets. J Clin Pharmacol.2015;55(4):452-457. doi: https://doi.org/10.1002/jcph.424

69. German A, Suraiya S, Tenenbaum-Rakover Y, et al. Control of ChildhoodCongenital Adrenal Hyperplasia and Sleep Activity and Quality withMorning or Evening Glucocorticoid Therapy. J Clin Endocrinol Metab.2008;93(12):4707-4710. doi: https://doi.org/10.1210/jc.2008-0519

70. Bonfig W, Dalla Pozza SB, Schmidt H, et al. HydrocortisoneDosing during Puberty in Patients with Classical CongenitalAdrenal Hyperplasia: An Evidence-Based Recommendation.J Clin Endocrinol Metab. 2009;94(10):3882-3888.doi: https://doi.org/10.1210/jc.2009-0942

71. Grigorescu-Sido A, Bettendorf M, Schulze E, et al. Growth Analysisin Patients with 21-Hydroxylase Deficiency Influence of GlucocorticoidDosage, Age at Diagnosis, Phenotype and Genotype on Growthand Height Outcome. Horm Res Paediatr. 2003;60(2):84-90.doi: https://doi.org/10.1159/000071876

72. Van der Kamp HJ. Longitudinal analysis of growth and pubertyin 21-hydroxylase deficiency patients. Arch Dis Child. 2002;87(2):139-144.doi: https://doi.org/10.1136/adc.87.2.139

73. Arlt W, Willis DS, Wild SH, et al. Health Status of Adults with CongenitalAdrenal Hyperplasia: A Cohort Study of 203 Patients. J Clin EndocrinolMetab. 2010;95(11):5110-5121. doi: https://doi.org/10.1210/jc.2010-0917

74. Finkielstain GP, Kim MS, Sinaii N, et al. Clinical Characteristics of a Cohortof 244 Patients with Congenital Adrenal Hyperplasia. J Clin EndocrinolMetab. 2012;97(12):4429-4438. doi: https://doi.org/10.1210/jc.2012-2102

75. Martin KA, Chang RJ, Ehrmann DA, et al. Evaluation and Treatmentof Hirsutism in Premenopausal Women: An Endocrine Society ClinicalPractice Guideline. J Clin Endocrinol Metab. 2008;93(4):1105-1120.doi: https://doi.org/10.1210/jc.2007-2437

76. El-Maouche D, Hargreaves CJ, Sinaii N, et al. Longitudinal Assessmentof Illnesses, Stress Dosing, and Illness Sequelae in PatientsWith Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab.2018;103(6):2336-2345. doi: https://doi.org/10.1210/jc.2018-00208

77. Taylor LK, Auchus RJ, Baskin LS, Miller WL. Cortisol response to operativestress with anesthesia in healthy children. J Clin Endocrinol Metab.2013;98(9):3687-3693. doi: https://doi.org/10.1210/jc.2013-2148

78. Reisch N, Willige M, Kohn D, et al. Frequency and causes of adrenal crisesover lifetime in patients with 21-hydroxylase deficiency. Eur J Endocrinol.2012;167(1):35-42. doi: https://doi.org/10.1530/EJE-12-0161

79. Weise M, Drinkard B, Mehlinger SL, et al. Stress Dose of HydrocortisoneIs Not Beneficial in Patients with Classic Congenital Adrenal HyperplasiaUndergoing Short-Term, High-Intensity Exercise. J Clin Endocrinol Metab.2004;89(8):3679-3684. doi: https://doi.org/10.1210/jc.2003-032051

80. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and Treatmentof Primary Adrenal Insufficiency: An Endocrine Society ClinicalPractice Guideline. J Clin Endocrinol Metab. 2016;101(2):364-389.doi: https://doi.org/10.1210/jc.2015-1710

81. Falhammar H, Nordenström A. Nonclassic congenital adrenalhyperplasia due to 21-hydroxylase deficiency: clinical presentation,diagnosis, treatment, and outcome. Endocrine. 2015;50(1):32-50.doi: https://doi.org/10.1007/s12020-015-0656-0

82. Trapp CM, Oberfield SE. Recommendations for treatment of nonclassiccongenital adrenal hyperplasia (NCCAH): An update. Steroids.2012;77(4):342-346. doi: https://doi.org/10.1016/j.steroids.2011.12.009

83. Spritzer P, Billaud L, Thalabard J-C, et al. Cyproterone AcetateVersus Hydrocortisone Treatment in Late-Onset AdrenalHyperplasia. J Clin Endocrinol Metab. 1990;70(3):642-646.doi: https://doi.org/10.1210/jcem-70-3-642

84. Matthews D, Cheetham T. What is the best approach to the teenagepatient presenting with nonclassical Congenital adrenal hyperplasia:should we always treat with glucocorticoids? Clin Endocrinol (Oxf).2013;78(3):338-341. doi: https://doi.org/10.1111/cen.12065

85. Moran C, Azziz R, Weintrob N, et al. Reproductive Outcomeof Women with 21-Hydroxylase-Deficient Nonclassic AdrenalHyperplasia. J Clin Endocrinol Metab. 2006;91(9):3451-3456.doi: https://doi.org/10.1210/jc.2006-0062

86. Bidet M, Bellanné-Chantelot C, Galand-Portier M-B, et al. Fertilityin Women with Nonclassical Congenital Adrenal Hyperplasia due to21-Hydroxylase Deficiency. J Clin Endocrinol Metab. 2010;95(3):1182-1190.doi: https://doi.org/10.1210/jc.2009-1383

87. Nandagopal R, Sinaii N, Avila NA, et al. Phenotypic profiling of parentswith cryptic nonclassic congenital adrenal hyperplasia: findingsin 145 unrelated families. Eur J Endocrinol. 2011;164(6):977-984.doi: https://doi.org/10.1530/EJE-11-0019

88. Stoupa A, Gonzalez-Briceno L, Pinto G, et al. Inadequate cortisolresponse to the tetracosactide (Synacthen ®) test in non-classiccongenital adrenal hyperplasia: an exception to the rule? Horm ResPaediatr. 2015;83(4):262-267. doi: https://doi.org/10.1159/000369901

89. Soboleva EL, Osinovskaya NS,Tkachenko NN, et al. Fertility recovery in patients with nonclassical congenital adrenal hyperplasia caused by 21-hydroxylasedeficiency. Problems of Endocrinology. 2018;64(2):79-84. (In Russ.).doi: https://doi.org/10.14341/probl8723

90. Nimkarn S, New MI. Steroid 11β- hydroxylase deficiency congenitaladrenal hyperplasia. Trends Endocrinol Metab. 2008;19(3):96-99.doi: https://doi.org/10.1016/j.tem.2008.01.002

91. Bulsari K, Falhammar H. Clinical perspectives in congenitaladrenal hyperplasia due to 11β-hydroxylase deficiency. Endocrine.2017;55(1):19-36. doi: https://doi.org/10.1007/s12020-016-1189-x

92. Migeon CJ. Over 50 Years of Progress in the Treatmentof the Hypertensive Form of Congenital Adrenal Hyperplasia dueto Steroid 11-Beta-Hydroxylase Deficiency. Horm Res Paediatr.2007;68(6):298-299. doi: https://doi.org/10.1159/000107652

93. Lesma A, Bocciardi A, Corti S, et al. Sexual Function in Adult LifeFollowing Passerini-Glazel Feminizing Genitoplasty in Patientswith Congenital Adrenal Hyperplasia. J Urol. 2014;191(1):206-211.doi: https://doi.org/10.1016/j.juro.2013.07.097

94. Houben C, Tsui S, Mou J, et al. Reconstructive surgery for females withcongenital adrenal hyperplasia due to 21-hydroxylase deficiency:a review from the Prince of Wales Hospital. Hong Kong Med J.2014;20(6):481-485. doi: https://doi.org/10.12809/hkmj144227

95. Yankovic F, Cherian A, Steven L, et al. Current practicein feminizing surgery for congenital adrenal hyperplasia;A specialist survey. J Pediatr Urol. 2013;9(6):1103-1107.doi: https://doi.org/10.1016/j.jpurol.2013.03.013

96. van der Zwan YG, Janssen EHCC, Callens N, et al. Severity of Virilization IsAssociated with Cosmetic Appearance and Sexual Function in Womenwith Congenital Adrenal Hyperplasia: A Cross‐Sectional Study. J Sex Med.2013;10(3):866-875. doi: https://doi.org/10.1111/jsm.12028

97. Binet A, Lardy H, Geslin D, et al. Should we question earlyfeminizing genitoplasty for patients with congenital adrenalhyperplasia and XX karyotype? J Pediatr Surg. 2016;51(3):465-468.doi: https://doi.org/10.1016/j.jpedsurg.2015.10.004

98. Pippi Salle JL, Lorenzo AJ, Jesus LE, et al. Surgical Treatment of HighUrogenital Sinuses Using the Anterior Sagittal Transrectal Approach:A Useful Strategy to Optimize Exposure and Outcomes. J Urol.2012;187(3):1024-1031. doi: https://doi.org/10.1016/j.juro.2011.10.162

99. Van Wyk JJ, Ritzen EM. The Role of Bilateral Adrenalectomyin the Treatment of Congenital Adrenal Hyperplasia.J Clin Endocrinol Metab. 2003;88(7):2993-2998.doi: https://doi.org/10.1210/jc.2002-022026

100. Ogilvie CM, Rumsby G, Kurzawinski T, Conway GS. Outcomeof bilateral adrenalectomy in congenital adrenal hyperplasia:one unit’s experience. Eur J Endocrinol. 2006;154(3):405-408.doi: https://doi.org/10.1530/eje.1.02096

101. Tiosano D, Vlodavsky E, Filmar S, et al. Ovarian Adrenal Rest Tumorin a Congenital Adrenal Hyperplasia Patient with AdrenocorticotropinHypersecretion following Adrenalectomy. Horm Res Paediatr.2010;74(3):223-228. doi: https://doi.org/10.1159/000295722

102. Crocker MK, Barak S, Millo CM, et al. Use of PET/CT with CosyntropinStimulation to Identify and Localize Adrenal Rest Tissuefollowing Adrenalectomy in a Woman with Congenital AdrenalHyperplasia. J Clin Endocrinol Metab. 2012;97(11):E2084-E2089.doi: https://doi.org/10.1210/jc.2012-2298

103. Tardy-Guidollet V, Menassa R, Costa J-M, et al. New ManagementStrategy of Pregnancies at Risk of Congenital Adrenal HyperplasiaUsing Fetal Sex Determination in Maternal Serum: French Cohortof 258 Cases (2002–2011). J Clin Endocrinol Metab. 2014;99(4):1180-1188.doi: https://doi.org/10.1210/jc.2013-2895

104. Ammini A, Eunice M. Prenatal treatment of mothers withfetuses at risk for congenital adrenal hyperplasia: How relevantis it to Indian context? Indian J Endocrinol Metab. 2013;17(3):373.doi: https://doi.org/10.4103/2230-8210.111596

105. New MI, Tong YK, Yuen T, et al. Noninvasive Prenatal Diagnosisof Congenital Adrenal Hyperplasia Using Cell-Free Fetal DNAin Maternal Plasma. J Clin Endocrinol Metab. 2014;99(6):E1022-E1030.doi: https://doi.org/10.1210/jc.2014-1118

106. Fernández-Balsells MM, Muthusamy K, Smushkin G, et al.Prenatal Dexamethasone Use For The Prevention Of VirilizationIn Pregnancies At Risk For Classical Congenital Adrenal Hyperplasiadue to 21 hydroxylase (CYP21A2) deficiency: A Systematic ReviewAnd Meta-Analyses. Clin Endocrinol (Oxf). 2010;73(4):436-444.doi: https://doi.org/10.1111/j.1365-2265.2010.03826.x

107. Miller WL, Witchel SF. Prenatal treatment of congenital adrenalhyperplasia: risks outweigh benefits. Am J Obstet Gynecol.2013;208(5):354-359. doi: https://doi.org/10.1016/j.ajog.2012.10.885

108. Rijk Y, Van Alfen-Van Der Velden J, Claahsen-Van Der Grinten HL.Prenatal treatment with dexamethasone in suspected congenitaladrenal hyperplasia and orofacial cleft: A case report and reviewof the literature. Pediatr Endocrinol Rev. 2017;372(9656):2143-2151.doi: https://doi.org/10.17458/per.vol15.2017.rvc.prenataltreatment

109. Murphy KE, Hannah ME, Willan AR, et al. Multiple coursesof antenatal corticosteroids for preterm birth (MACS):a randomised controlled trial. Lancet. 2008;372(9656):2143-2151.doi: https://doi.org/10.1016/S0140-6736(08)61929-7

110. Hirvikoski T, Nordenström A, Lindholm T, et al. Long-term follow-upof prenatally treated children at risk for congenital adrenal hyperplasia:does dexamethasone cause behavioural problems? Eur J Endocrinol.2008;159(3):309-316. doi: https://doi.org/10.1530/EJE-08-0280

111. Hirvikoski T, Nordenström A, Wedell A, et al. Prenatal DexamethasoneTreatment of Children at Risk for Congenital Adrenal Hyperplasia:The Swedish Experience and Standpoint. J Clin Endocrinol Metab.2012;97(6):1881-1883. doi: https://doi.org/10.1210/jc.2012-1222

112. Dörr H, Binder G, Reisch N, et al. Expertsʼ Opinion onthe Prenatal Therapy of Congenital Adrenal Hyperplasia (CAH)Due to 21-Hydroxylase Deficiency – Guideline of DGKEDin cooperation with DGGG (S1-Level, AWMF Registry No. 174/013,July 2015). Geburtshilfe Frauenheilkd. 2015;75(12):1232-1238.doi: https://doi.org/10.1055/s-0041-109717

113. Simpson JL, Rechitsky S. Preimplantation diagnosis and othermodern methods for prenatal diagnosis. J Steroid Biochem Mol Biol.2017;165:124-130. doi: https://doi.org/10.1016/j.jsbmb.2016.03.022

114. Meyer-Bahlburg HFL. Psychoendocrinology of congenital adrenalhyperplasia. In: New MI. Ed by Lekarev O, Parsa A, Yuen et al. GeneticSteroid Disorders. San Diego, CA: Academic Press; 2014. P. 285-300.

115. Al-Maghribi H. Congenital adrenal hyperplasia: problems withdevelopmental anomalies of the external genitalia and sex assignment.Saudi J Kidney Dis Transpl. 2007;18(3):405-413.

116. Chowdhury TK, Laila K, Hutson JM, Banu T. Male gender identity in childrenwith 46,XX DSD with congenital adrenal hyperplasia after delayedpresentation in mid-childhood. J Pediatr Surg. 2015;50(12):2060-2062.doi: https://doi.org/10.1016/j.jpedsurg.2015.08.023

117. Meyer-Bahlburg HFL. Gender Monitoring and Gender Reassignmentof Children and Adolescents with a Somatic Disorder of SexDevelopment. Child Adolesc Psychiatr Clin N Am. 2011;20(4):639-649.doi: https://doi.org/10.1016/j.chc.2011.07.002

118. Lee PA, Houk CP, Husmann DA. Should Male Gender Assignmentbe Considered in the Markedly Virilized Patient With 46,XX andCongenital Adrenal Hyperplasia? J Urol. 2010;184(4S):1786-1792.doi: https://doi.org/10.1016/j.juro.2010.03.116

119. Meyer-Bahlburg HFL, Dolezal C, Baker SW, et al. GenderDevelopment in Women with Congenital Adrenal Hyperplasia asa Function of Disorder Severity. Arch Sex Behav. 2006;35(6):667-684.doi: https://doi.org/10.1007/s10508-006-9068-9

120. Hines M, Constantinescu M, Spencer D. Early androgen exposureand human gender development. Biol Sex Differ. 2015;6(1):3.doi: https://doi.org/10.1186/s13293-015-0022-1

121. Meyer-Bahlburg HFL, Baratz Dalke K, Berenbaum SA, et al. GenderAssignment, Reassignment and Outcome in Disorders of SexDevelopment: Update of the 2005 Consensus Conference. Horm ResPaediatr. 2016;85(2):112-118. doi: https://doi.org/10.1159/000442386

122. Hines M, Pasterski V, Spencer D, et al. Prenatal androgenexposure alters girls’ responses to information indicatinggender-appropriate behaviour. Philos Trans R Soc B Biol Sci. 2016.doi: https://doi.org/10.1098/rstb.2015.0125

123. Endendijk JJ, Beltz AM, McHale SM, et al. Linking Prenatal Androgensto Gender-Related Attitudes, Identity, and Activities: EvidenceFrom Girls With Congenital Adrenal Hyperplasia. Arch Sex Behav.2016;45(7):1807-1815. doi: https://doi.org/10.1007/s10508-016-0693-7

124. Pasterski V, Zucker KJ, Hindmarsh PC, et al. Increased Cross-GenderIdentification Independent of Gender Role Behavior in Girls withCongenital Adrenal Hyperplasia: Results from a StandardizedAssessment of 4- to 11-Year-Old Children. Arch Sex Behav.2015;44(5):1363-1375. doi: https://doi.org/10.1007/s10508-014-0385-0

125. Dessens AB, Slijper FME, Drop SLS. Gender Dysphoria andGender Change in Chromosomal Females with CongenitalAdrenal Hyperplasia. Arch Sex Behav. 2005;34(4):389-397.doi: https://doi.org/10.1007/s10508-005-4338-5

126. Meyer-Bahlburg HFL. Gender Assignment and Reassignmentin Intersexuality: Controversies, Data, and Guidelines for Research.Advances in Experimental Medicine and Biology. 2002;511:199-223.doi: https://doi.org/10.1007/978-1-4615-0621-8_12

127. Liao L-M, Wood D, Creighton SM. Parental choice on normalisingcosmetic genital surgery. BMJ. September 2015;351:5124.doi: https://doi.org/10.1136/bmj.h5124

128. Tamar-Mattis A. Patient advocate responds to DSDsurgery debate. J Pediatr Urol. 2014;10(4):788-789.doi: https://doi.org/10.1016/j.jpurol.2014.03.019

129. Sytsma SE. Ethics and Intersex. Dordrecht, Netherlands: SpringerNetherlands; 2006.

130. Feder EK, Dreger A. Still ignoring human rights in intersex care. J PediatrUrol. 2016;12(6):436-437. doi: https://doi.org/10.1016/j.jpurol.2016.05.017

131. Dreger AD. Intersex and human rights: the long view. In: Sytsma SE, editor.Ethics and Intersex. Dordrecht, Netherlands: Springer; 2006: P. 73-86.

132. Diamond M, Beh HG. The right to be wrong: sex and gender decisions.In: Sytsma SE, editor. Ethics and Intersex. Dordrecht, Netherlands: Springer;2006. P. 103-114.

133. Creighton SM. Adult outcomes of feminizing surgery. In: Sytsma SE, editor.Ethics and Intersex. Dordrecht, Netherlands: Springer; 2006. P. 207-214.

134. Diamond M, Sigmundson HK. Managementof Intersexuality: Guidelines for Dealing With PersonsWith Ambiguous Genitalia. J Urol. 1998;159(4):1407-1407.doi: https://doi.org/10.1016/S0022-5347(01)63644-9

135. Wisniewski AB, Migeon CJ, Malouf MA, Gearhart JP. Psychosexualoutcome in women affected by congenital adrenal hyperplasiadue to 21-hydroxylase deficiency. J Urol. 2004;171(6P1):2497-2501.doi: https://doi.org/10.1097/01.ju.0000125269.91938.f7

136. Fagerholm R, Santtila P, Miettinen PJ, et al. Sexual Function andAttitudes Toward Surgery After Feminizing Genitoplasty. J Urol.2011;185(5):1900-1904. doi: https://doi.org/10.1016/j.juro.2010.12.099

137. Zhang H, Pan J, Ji H, et al. Long-Term Evaluation of PatientsUndergoing Genitoplasty due to Disorders of Sex Development:Results from a 14-Year Follow-Up. Sci World J. 2013;2013:1-7.doi: https://doi.org/10.1155/2013/298015

138. Dayner JE, Lee PA, Houk CP. Medical treatmentof intersex: parental perspectives. J Urol. 2004;172(4P2):1762-1765.doi: https://doi.org/10.1097/01.ju.0000138519.12573.3a

139. Lundberg T, Lindström A, Roen K, Hegarty P. From knowing nothingto knowing what, how and now: parents’ experiences of caring fortheir children with congenital adrenal hyperplasia. J Pediatr Psychol.2017;42(5):520-529. doi: https://doi.org/10.1093/jpepsy/jsw001

140. Reisch N, Hahner S, Bleicken B, et al. Quality of life is less impaired in adultswith congenital adrenal hyperplasia because of 21-hydroxylase deficiencythan in patients with primary adrenal insufficiency. Clin Endocrinol (Oxf).2011;74(2):166-173. doi: https://doi.org/10.1111/j.1365-2265.2010.03920.x

141. King TFJ, Lee MC, Williamson EEJ, Conway GS. Experience in optimizingfertility outcomes in men with congenital adrenal hyperplasia due to21 hydroxylase deficiency. Clin Endocrinol (Oxf). 2016;84(6):830-836.doi: https://doi.org/10.1111/cen.13001

142. Casteràs A, De Silva P, Rumsby G, Conway GS. Reassessingfecundity in women with classical congenital adrenalhyperplasia (CAH): normal pregnancy rate but reducedfertility rate. Clin Endocrinol (Oxf). 2009;70(6):833-837.doi: https://doi.org/10.1111/j.1365-2265.2009.03563.x.

143. Debono M, Mallappa A, Gounden V, et al. Hormonal circadian rhythmsin patients with congenital adrenal hyperplasia: identifying optimalmonitoring times and novel disease biomarkers. Eur J Endocrinol.2015;173(6):727-737. doi: https://doi.org/10.1530/EJE-15-0064

144. Tamhane S, Rodriguez-Gutierrez R, Iqbal AM, et al. Cardiovascularand Metabolic Outcomes in Congenital Adrenal Hyperplasia:A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab.2018;103(11):4097-4103. doi: https://doi.org/10.1210/jc.2018-01862

145. Völkl TMK, Simm D, Körner A, et al. Does an altered leptin axis play a rolein obesity among children and adolescents with classical congenitaladrenal hyperplasia due to 21-hydroxylase deficiency? Eur J Endocrinol.2009;160(2):239-247. doi: https://doi.org/10.1530/EJE-08-0770

146. Volkl TMK. Obesity Among Children and AdolescentsWith Classic Congenital Adrenal Hyperplasia Due to21-Hydroxylase Deficiency. Pediatrics. 2006;117(1):e98-e105.doi: https://doi.org/10.1542/peds.2005-1005

147. Cornean RE, Hindmarsh PC, Brook CGD. Obesity in 21-hydroxylasedeficient patients. Arch Dis Child. 1998;78(3):261-263.doi: https://doi.org/10.1136/adc.78.3.261

148. Сазонова А.И., Трошина Е.А., Молашенко Н.В. Метаболическиенарушения у взрослых пациентов с врожденной дисфункцией корынадпочеников Проблемы эндокринологии. 2012. Т58. №5. С. 3-9.

149. Falhammar H, Filipsson H, Holmdahl G, et al. Fractures andBone Mineral Density in Adult Women with 21-HydroxylaseDeficiency. J Clin Endocrinol Metab. 2007;92(12):4643-4649.doi: https://doi.org/10.1210/jc.2007-0744

150. Ceccato F, Barbot M, Albiger N, et al. Long-term glucocorticoid effect onbone mineral density in patients with congenital adrenal hyperplasiadue to 21-hydroxylase deficiency. Eur J Endocrinol. 2016;175(2):101-106.doi: https://doi.org/10.1530/EJE-16-0104

151. Chakhtoura Z, Bachelot A, Samara-Boustani D, et al. Impact of totalcumulative glucocorticoid dose on bone mineral density in patientswith 21-hydroxylase deficiency. Eur J Endocrinol. 2008;158(6):879-887.doi: https://doi.org/10.1530/EJE-07-0887

152. Bachelot A, Chakhtoura Z, Samara-Boustani D, et al. Bone HealthShould Be an Important Concern in the Care of Patients Affectedby 21 Hydroxylase Deficiency. Int J Pediatr Endocrinol. 2010;2010:1-7.doi: https://doi.org/10.1155/2010/326275

153. Сазонова А.И., Молашенко Н.В., Трошина Е.А. Влияниеглюкокортикоидной терапии врожденной дисфункции корынадпочечников у взрослых пациентов на снижение минеральнойкостной плотности. Остеопороз и остеопатии.2014. Т.16. №4. С 63-67.

154. Barzon L, Sonino N, Fallo F, et al. Prevalence and natural historyof adrenal incidentalomas. Eur J Endocrinol. October 2003;149:273-285.doi: https://doi.org/10.1530/eje.0.1490273

155. Varan A, Unal S, Ruacan S, Vidinlisan S. Adrenocortical carcinomaassociated with adrenogenital syndrome in a child. Med PediatrOncol. 2000;35(1):88-90. doi: https://doi.org/10.1002/1096-

156. 911X(200007)35:1<88::AID-MPO18>3.0.CO;2-I

157. Jaresch S, Kornely E, Kley HK, Schlaghecke R. Adrenal incidentalomaand patients with homozygous or heterozygous congenitaladrenal hyperplasia. J Clin Endocrinol Metab. 1992;74(3):685-689.doi: https://doi.org/10.1210/jcem.74.3.1311000

158. Barzon L, Maffei P, Sonino N, et al. The role of 21-hydroxylasein the pathogenesis of adrenal masses: Review of the literature andfocus on our own experience. J Endocrinol Invest. 2007;30(7):615-623.doi: https://doi.org/10.1007/BF03346358

159. Falhammar H, Frisén L, Norrby C, et al. Reduced Frequency of Biologicaland Increased Frequency of Adopted Children in Males With21-Hydroxylase Deficiency: A Swedish Population-Based NationalCohort Study. J Clin Endocrinol Metab. 2017;102(11):4191-4199.doi: https://doi.org/10.1210/jc.2017-01139

160. Kavoussi PK, Summers-Colquitt RB, Odenwald KC, et al. Spermretrieval and concomitant tumor resection in azoospermic menwith congenital adrenal hyperplasia and bilateral testicular adrenalrest tumors: a case report. J Assist Reprod Genet. 2016;33(4):545-548.doi: https://doi.org/10.1007/s10815-016-0665-9

161. Сазонова А.И., Молашенко Н.В., Трошина Е.А. Состояниерепродуктивной функции и критерии компенсации у взрослыхпациентов с классическими формами врожденной дисфункциикоры надпочечников // Consilium Medicum. — 2014. — Т. 16. —№4. — С. 63-67. [Sazonova AI, Molashenko NV, Troshina EA. Sostoyaniereproduktivnoi funktsii i kriterii kompensatsii u vzroslykh patsientovs klassicheskimi formami vrozhdennoi disfunktsii kory nadpochechnikov.Consilium Medicum. 2014;16(4):63-67. (In Russ.)].

162. Mellis AM, Palmer BW, Wisniewski AB, Slobodov G. Ovarianadrenal rest tumour in a patient with chronically untreatedcongenital adrenal hyperplasia (CAH). BJUI. July 2011.doi: https://doi.org/10.1002/BJUIw-2011-041-web

163. Chew KT, Abu MA, Arifuddin Y, et al. Ectopic adrenal tissue associatedwith borderline mucinous cystadenoma of ovary: a case reportwith review of the literature. Horm Mol Biol Clin Investig. 2017;32(3).doi: https://doi.org/10.1515/hmbci-2017-0021

164. Tiosano D, Vlodavsky E, Filmar S, et al. Ovarian Adrenal Rest Tumorin a Congenital Adrenal Hyperplasia Patient with AdrenocorticotropinHypersecretion following Adrenalectomy. Horm Res Paediatr.2010;74(3):223-228. doi: https://doi.org/10.1159/000295722

165. Stikkelbroeck NML, Hermus AMM, Schouten D, et al. Prevalence of ovarianadrenal rest tumours and polycystic ovaries in females with congenitaladrenal hyperplasia: results of ultrasonography and MR imaging. Eur Radiol.2004;14(10). doi: https://doi.org/10.1007/s00330-004-2329-x

166. Zaarour M, Atallah D, Trak-Smayra V, Halaby G. Bilateral Ovary Adrenal RestTumor in a Congenital Adrenal Hyperplasia Following Adrenalectomy.Endocr Pract. 2014;20(4):e69-e74. doi: https://doi.org/10.4158/EP13092.CR

167. Bulsari K, Falhammar H. 11β-Hydroxylase Deficiency. In:Encyclopedia of Endocrine Diseases. Vol 55. Elsevier; 2019:421-430.doi: https://doi.org/10.1016/B978-0-12-801238-3.65823-3

168. Bulsari K, Falhammar H. Clinical perspectives in congenitaladrenal hyperplasia due to 11β-hydroxylase deficiency. Endocrine.2017;55(1):19-36. doi: https://doi.org/10.1007/s12020-016-1189-x

169. Lurbe E, Cifkova R, Cruickshank JK, et al. Management of high bloodpressure in children and adolescents: recommendations of the EuropeanSociety of Hypertension. J Hypertens. 2009;27(9):1719-1742.doi: https://doi.org/10.1097/HJH.0b013e32832f4f6b

170. Zacharieva S, Robeva R, Andonova S, et al. Long-term follow-upof a female patient with non-classical 11 β -hydroxylase deficiency andtwo novel mutations in CYP11B1. Gynecol Endocrinol. 2019;35(1):23-27.doi: https://doi.org/10.1080/09513590.2018.1482870

171. Lo JC, Schwitzgebel VM, Tyrrell JB, et al. Normal Female Infants Bornof Mothers with Classic Congenital Adrenal Hyperplasia due to21-Hydroxylase Deficiency 1. J Clin Endocrinol Metab. 1999;84(3):930-936.doi: https://doi.org/10.1210/jcem.84.3.5565

172. Hagenfeldt K, Janson PO, Holmdahl G, et al. Fertility and pregnancyoutcome in women with congenital adrenal hyperplasia due to21-hydroxylase deficiency. Hum Reprod. 2008;23(7):1607-1613.doi: https://doi.org/10.1093/humrep/den118

173. Dedov II,Krasnopol’skiy VI, Sukhikh GT — on behalf of the research group. RussianNational Consensus Statement on gestational diabetes: diagnostics,treatment and postnatal care. Diabetes mellitus. 2012;(4):4-10 (In Russ.).

174. Moyer VA. Screening for Gestational Diabetes Mellitus: U.S. PreventiveServices Task Force Recommendation Statement. Ann Intern Med.2014;160(6):414-420. doi: https://doi.org/10.7326/M13-2905

175. Falhammar H, Filipsson H, Holmdahl G, et al. Metabolic Profile and BodyComposition in Adult Women with Congenital Adrenal Hyperplasia dueto 21-Hydroxylase Deficiency. J Clin Endocrinol Metab. 2007;92(1):110-116.doi: https://doi.org/10.1210/jc.2006-1350

176. Bidet M, Bellanné-Chantelot C, Galand-Portier M-B, et al. Fertilityin Women with Nonclassical Congenital Adrenal Hyperplasia due to21-Hydroxylase Deficiency. J Clin Endocrinol Metab. 2010;95(3):1182-1190.doi: https://doi.org/10.1210/jc.2009-1383

177. Eyal O, Ayalon-Dangur I, Segev-Becker A, et al. Pregnancyin women with nonclassic congenital adrenal hyperplasia: Time toconceive and outcome. Clin Endocrinol (Oxf). 2017;87(5):552-556.doi: https://doi.org/10.1111/cen.13429

178. Carmina E, Dewailly D, Escobar-Morreale HF, et al. Non-classic congenitaladrenal hyperplasia due to 21-hydroxylase deficiency revisited: an updatewith a special focus on adolescent and adult women. Hum Reprod Update.2017;23(5):580-599. doi: https://doi.org/10.1093/humupd/dmx014

179. Flint JL, Jacobson JD. Adrenal Hypoplasia Congenita Presenting asCongenital Adrenal Hyperplasia. Case Rep Endocrinol. 2013;2013:1-4.doi: https://doi.org/10.1155/2013/393584